Aragen Bioscience Announces Cooperative Research and Development Agreement with the U.S. Army2018-10-26T02:19:42+00:00

Aragen Bioscience Announces Cooperative Research and Development Agreement with the U.S. Army

01-Jun-2011

MORGAN HILL, Calif.–(BUSINESS WIRE)–Aragen Bioscience, Inc., a California based Custom Research Services Organization, announced today a Cooperative Research and Development Agreement (CRADA) to work with the U.S. Army Edgewood Chemical and Biological Center (US ARMY ECBC) at Aberdeen Proving Ground.  Under the terms of the agreement, Aragen Bioscience will offer its broad portfolio of research services to the US ARMY ECBC, including expression, stable cell line development, process development, cell based assay development and a wide range of GLP and non-GLP in vivo human disease models. The US ARMY ECBC in turn, will offer their resources in fermentation and cryopresevation to Aragen Bioscience for use in Aragen’s client projects.

Rick Srigley, President and CEO of Aragen Bioscience, is pleased to be working with the US ARMY ECBC and looks forward to collaborative efforts that will address the needs of Aragen’s clients. “It couples the ingenuity and scientific skills of our two teams with the exceptional offerings and cutting edge support located at Aragen Bioscience.  The US ARMY ECBC has a long and successful track record working with the private sector to produce biological products and developing relationships with companies such as Aragen Bioscience“.

“Our Relationship with Aragen Bioscience will add a new dimension to the success of the US ARMY ECBC’s partnerships with the private sector,” said the US Army ECBC.  “Many types of biopharmaceutical development projects will benefit from the cell culture, fermentation, filtration, purification, assay development, formulation and in vivo research services able to be executed jointly by Aragen Bioscience and the US ARMY ECBC under this agreement.”

About Aragen Bioscience
Aragen Bioscience, Inc., is a research and development services company located in the San Francisco Bay area. Aragen Bioscience specializes in recombinant cell line and hybridoma development, cell culture and protein purification process development and production, primary and immortalized cell-based assays, in vivo models of human disease and custom immunological services. For more information, visit www.aragenbio.com.